Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Kato S., Ohno T., Thephamongkhol K., Chansilpa Y., Yuxing Y., Beena Devi C.R., Bustam A.Z., Calaguas M.J.C., de los Reyes R.H., Cho C.-K., Dung T.A., Supriana N., Mizuno H., Nakano T., Tsujii H.
57201751207;35395665700;6506860951;6603351348;36143620600;36061300700;12809503500;8452403700;20733282500;24782144200;20734288500;8438653200;7202780324;57191501505;7006202764;
Multi-Institutional Phase II Clinical Study of Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer in East and Southeast Asia
2010
International Journal of Radiation Oncology Biology Physics
77
3
751
757
19
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan; Gunma University Heavy Ion Medical Center, Gunma University, Gunma, Japan; Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Bangkok, Thailand; Department of Gynecologic Oncology, Changzhou Tumor Hospital, Changzhou, China; Department of Radiotherapy and Oncology, Sarawak General Hospital, Kuching, Malaysia; Clinical Oncology Unit, University of Malaya Faculty of Medicine, Kuala Lumpur, Malaysia; Department of Radiation Oncology, St. Luke's Medical Center, Quezon City, Philippines; Department of Obstetrics and Gynecology, Dr. Jose R. Reyes Memorial Medical Center, Manila, Philippines; Department of Radiation Oncology, Korea Cancer Center Hospital, Seoul, South Korea; Department of Breast and Gynecology Radiotherapy, National Cancer Institute, Hanoi, Viet Nam; Department of Radiation Therapy, University of Indonesia Faculty of Medicine, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan
Kato, S., Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan; Ohno, T., Gunma University Heavy Ion Medical Center, Gunma University, Gunma, Japan; Thephamongkhol, K., Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Bangkok, Thailand; Chansilpa, Y., Division of Radiation Oncology, Department of Radiology, Siriraj Hospital, Bangkok, Thailand; Yuxing, Y., Department of Gynecologic Oncology, Changzhou Tumor Hospital, Changzhou, China; Beena Devi, C.R., Department of Radiotherapy and Oncology, Sarawak General Hospital, Kuching, Malaysia; Bustam, A.Z., Clinical Oncology Unit, University of Malaya Faculty of Medicine, Kuala Lumpur, Malaysia; Calaguas, M.J.C., Department of Radiation Oncology, St. Luke's Medical Center, Quezon City, Philippines; de los Reyes, R.H., Department of Obstetrics and Gynecology, Dr. Jose R. Reyes Memorial Medical Center, Manila, Philippines; Cho, C.-K., Department of Radiation Oncology, Korea Cancer Center Hospital, Seoul, South Korea; Dung, T.A., Department of Breast and Gynecology Radiotherapy, National Cancer Institute, Hanoi, Viet Nam; Supriana, N., Department of Radiation Therapy, University of Indonesia Faculty of Medicine, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Mizuno, H., Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan; Nakano, T., Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan; Tsujii, H., Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
Purpose: To evaluate the toxicity and efficacy of concurrent chemoradiotherapy using weekly cisplatin for patients with locally advanced cervical cancer in East and Southeast Asia, a multi-institutional Phase II clinical study was conducted among eight Asian countries. Methods and Materials: Between April 2003 and March 2006, 120 patients (60 with bulky Stage IIB and 60 with Stage IIIB) with previously untreated squamous cell carcinoma of the cervix were enrolled in the present study. Radiotherapy consisted of pelvic external beam radiotherapy (total dose, 50 Gy) and either high-dose-rate or low-dose-rate intracavitary brachytherapy according to institutional practice. The planned Point A dose was 24-28 Gy in four fractions for high-dose-rate-intracavitary brachytherapy and 40-45 Gy in one to two fractions for low-dose-rate-intracavitary brachytherapy. Five cycles of weekly cisplatin (40 mg/m2) were administered during the radiotherapy course. Results: All patients were eligible for the study. The median follow-up was 27.3 months. Of the 120 patients, 100 (83%) received four or five cycles of chemotherapy. Acute Grade 3 leukopenia was observed in 21% of the patients, and Grade 3 gastrointestinal toxicity was observed in 6%. No patient failed to complete the radiotherapy course because of toxicity. The 2-year local control and overall survival rate for all patients was 87.1% and 79.6%, respectively. The 2-year major late rectal and bladder complication rate was 2.5% and 0%, respectively. Conclusion: The results have suggested that concurrent chemoradiotherapy using weekly cisplatin is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia. © 2010 Elsevier Inc. All rights reserved.
Cervical cancer; chemoradiotherapy; developing country; high-dose-rate brachytherapy; international clinical study
Asian countries; Brachytherapy; Cervical cancers; Chemoradiotherapy; Cis-platin; Clinical study; Concurrent chemoradiotherapy; External beam radiotherapy; Gastrointestinal toxicities; High dose rate; High-dose rate brachytherapy; Local control; Low dose rate; Overall survival rates; Phase II; Southeast Asia; Squamous cell carcinoma; Total dose; Chemotherapy; Developing countries; Oncology; Platinum compounds; Societies and institutions; Toxicity; Radiotherapy; cisplatin; creatinine; adult; advanced cancer; aged; article; bladder disease; brachytherapy; cancer chemotherapy; cancer control; cancer radiotherapy; cancer staging; chemotherapy induced emesis; clinical effectiveness; clinical trial; creatinine blood level; external beam radiotherapy; female; gastrointestinal toxicity; human; leuk
03603016
IOBPD
19836154
Article
Q1